Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 19

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
$1,989 $2,247 $4,470 $4,280 Research and development12,613 17,862 26,719 34,750 Selling, general and administrative12,643 18,383 27,132 35,591 Total stock-based compensation expense$27,245 $38,492 $58,321 $74,621 Restricted Stock UnitsRestricted stock units (“RSUs”) activity for the six months ended June 30, 2025 is as follows:Restricted StockUnitsWeighted-AverageGrant Date Fair Value(per share)Outstanding as of December 31, 20246,493,387 $35.55 Granted4,801,774 10.22 Vested(1,407,413)36.29 Cancelled(731,363)30.52 Outstanding as of June 30, 20259,156,385 $22.56 Stock OptionsStock option activity for the six months ended June 30, 2025 is as follows:Stock OptionsWeighted-AverageExercise PriceOutstanding as of December 31, 20244,594,582 $45.37 Exercised(296,116)1.63 Cancelled and forfeited(328,744)58.94 Outstanding as of June 30, 20253,969,722 $47.51 Performance Stock Awards In March 2025, the Company granted 561,603 performance stock units (“PSUs”) under the 2019 Omnibus Incentive Plan (“2019 plan”) to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below:

16

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

i.50% of target PSUs earned will be based on the Company’s compound annual growth rate (“CAGR”) of the Company’s Revenue over a two-year performance period from January 1, 2025 to December 31, 2026. Holders may earn from 0% to 200% of the target amount of shares and earned PSUs will then be subject to service-based vesting; andii.50% of target PSUs earned will be based on the relative Total Shareholder Return (“TSR”) of the Company’s Class A